Search NLS News

Data from the phase 3 OCEAN study, evaluating the efficacy and safety of melflufen plus dexamethasone versus pomalidomide plus dexamethasone in lenalidomide refractory patients with relapsed refractory multiple myeloma that have received 2-4 prior lines of therapy, have been published in the Lancet Hematology. The OCEAN study was initiated in 2017 and includes 495 patients […]

Updated results from the ASCEND Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) maintained a statistically significant progression-free survival (PFS) benefit at three years compared to investigator’s choice of rituximab combined with either idelalisib (IdR) or bendamustine (BR) in adults with relapsed or refractory chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults. […]

Alligator Bioscience has announced the initiation a sponsored research collaboration to study biomarker data from Alligator’s OPTIMIZE-1 study with the University of Pennsylvania’s (UPENN) Pancreatic Cancer Research Center. Gregory Beatty, assistant professor of Medicine in the Division of Hematology/Oncology, UPENN, will serve as the faculty investigator for the sponsored Research agreements. Data analysis by Dr. […]

Sigrid Therapeutics has announced that the results from their Proof-of-Concept STAR study have been published in Nanomedicine. Oral administration of the company’s lead product SiPore15 to subjects with prediabetes or newly diagnosed type 2 diabetes resulted in a significant and clinically meaningful reduction in HbA1c, a key marker of glucose control, states the company. The […]

Lars Ekman from Gothenburg, Sweden, has more than 30 years experience in senior executive, scientific, and clinical functions within life sciences across the globe. He is today capitalizing on his extensive knowledge and sharing his experience as Executive Partner at Sofinnova Investments in the USA. Lars Ekman’s career path has taken him from Sweden to […]

A new study from Karolinska Institutet shows that T cells still recognize omicron after infection with previous variants of SARS-CoV-2 or vaccination. The omicron variant can partly evade the antibody response provided by vaccination or infection with previous variants of SARS-CoV-2. However, T cells still recognize omicron, the scientists report in a study published in […]

Scientists have identified some genetic variants in people that may more likely lose their ability to taste and smell. The study, published in Nature Genetics, investigated nearly 70,000 adults with COVID-19 and found that persons with certain genetic tweaks on chromosome 4 were 11 percent more likely to lose the ability to smell and taste […]

Nykode Therapeutics has announced that the first subject has been dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate in its VB-D-01 Phase 1/2 trial. The T cell specific vaccine is designed to prime T cells, potentially generating a broad immune response against current and future variants. The VB-D-01 trial is a two-arm, open […]

Akademiska Hus is investing 160 million SEK in reconstructing Fysiologen into modern offices and laboratories. The reconstruction is planned to begin in February 2022 and ready for occupation, in stages, during 2023. A vivid life science district Campus Solna, connecting Stockholm and Solna, has become a vivid new district, consisting of accommodations, commerce, subway, culture […]

Elicera Therapeutics has announced that Vinnova has granted the company and its project partners 5 million SEK in grants to develop an automated process for CAR T-cell manufacturing. Elicera Therapeutics and its collaborators at Karolinska Institute and their production unit, Vecura at Karolinska Sjukhuset, Uppsala University and Akademiska Sjukhuset in Uppsala are preparing for a […]